Published in Gene Ther on March 22, 2007
Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther (2009) 1.13
Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther (2007) 0.99
The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors. Cancer Gene Ther (2013) 0.85
Evaluation of adenovirus capsid labeling versus transgene expression. Virol J (2010) 0.78
Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro. Virol J (2010) 0.78
Oncolytic virotherapy: the questions and the promise. Oncolytic Virother (2013) 0.75
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med (1998) 8.47
A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis (2006) 1.81
Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum Mol Genet (1999) 1.79
LKB1 somatic mutations in sporadic tumors. Am J Pathol (1999) 1.79
Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res (1996) 1.77
Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. Cancer Res (1998) 1.75
Identification by molecular cloning of an autoantigen associated with Addison's disease as steroid 17 alpha-hydroxylase. Lancet (1992) 1.73
Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Res (1997) 1.47
Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines. Arch Virol (1994) 1.34
Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3. J Med Genet (1998) 1.27
Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol (2011) 1.26
Breast cancer metastasis to bone: evaluation of bioluminescent imaging and microSPECT/CT for detecting bone metastasis in immunodeficient mice. Clin Exp Metastasis (2007) 1.24
Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther (2010) 1.19
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther (2011) 1.16
SMAD genes in juvenile polyposis. Genes Chromosomes Cancer (1999) 1.10
Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther (2005) 1.08
Mitochondrial DNA mutations in black Americans with hypertension-associated end-stage renal disease. Am J Kidney Dis (2001) 1.05
Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther (2004) 1.04
Successful amplification of DNA specific for Finnish Borrelia burgdorferi isolates in erythema chronicum migrans but not in circumscribed scleroderma lesions. J Invest Dermatol (1994) 1.04
Crystal-structure-dependent photoluminescence from InP nanowires. Nanotechnology (2006) 1.02
Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta. Proc Natl Acad Sci U S A (1999) 1.02
Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison's disease. J Clin Endocrinol Metab (1994) 1.01
Oncolytic adenovirus based on serotype 3. Cancer Gene Ther (2010) 0.99
Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res (2001) 0.98
Random mutagenesis used to probe the structure and function of Bacillus stearothermophilus alpha-amylase. Protein Eng (1990) 0.97
Reducing the cost of diagnosis of breast carcinoma: impact of ultrasound and imaging-guided biopsies on a clinical breast practice. Cancer (2001) 0.97
Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther (2005) 0.97
Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res (2001) 0.95
Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat. FASEB J (1995) 0.93
The conserved UL24 family of human alpha, beta and gamma herpesviruses induces cell cycle arrest and inactivation of the cyclinB/cdc2 complex. Arch Virol (2009) 0.93
Employment of liver tissue slice analysis to assay hepatotoxicity linked to replicative and nonreplicative adenoviral agents. Cancer Gene Ther (2006) 0.92
Molecular control of transgene escape from genetically modified plants. Plant Sci (2001) 0.92
Biodiversity of zooplankton communities in the Upper Paraná River floodplain: interannual variation from long-term studies. Braz J Biol (2009) 0.91
Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus. Gene Ther (2007) 0.91
A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy. Gene Ther (2005) 0.90
Green fluorescent protein (GFP) fusion constructs in gene therapy research. Histochem Cell Biol (2001) 0.90
In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders. Int J Cancer (2013) 0.88
Time trends in survival from cancer of unknown primary: small steps forward. Eur J Cancer (2013) 0.88
Genetic changes in the RNA components of RNase MRP and RNase P in Schmid metaphyseal chondrodysplasia. J Med Genet (2003) 0.88
A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Ther (2006) 0.87
Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Ther (2003) 0.87
An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol Oncol (2001) 0.86
A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther (2004) 0.86
Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Ther (2008) 0.86
Protocol core needle biopsy and histological chronic allograft damage index as surrogate endpoint for Long-Term graft survival. Transplant Proc (2004) 0.85
Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries? Ann Oncol (2012) 0.84
Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells. Gene Ther (2011) 0.84
Femoropopliteal angioplasty in patients with claudication: primary and secondary patency in 140 limbs with 1-3-year follow-up. Radiology (1994) 0.84
Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res (2001) 0.83
Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. Gene Ther (2009) 0.82
Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther (2002) 0.82
Role of platelet-derived growth factor in obliterative bronchiolitis (chronic rejection) in the rat. Am J Respir Crit Care Med (1999) 0.82
Site-specific cancer deaths in cancer of unknown primary diagnosed with lymph node metastasis may reveal hidden primaries. Int J Cancer (2012) 0.81
A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. Gene Ther (2009) 0.81
X-ray studies of recombinant anti-testosterone Fab fragments: the use of PEG 3350 in crystallization. Acta Crystallogr D Biol Crystallogr (2000) 0.81
Auditing a nationwide vascular registry--the 4-year Finnvasc experience. Finnvasc Study Group. Eur J Vasc Endovasc Surg (1997) 0.80
Role of nitric oxide in experimental obliterative bronchiolitis (chronic rejection) in the rat. J Clin Invest (1997) 0.80
Cancer gene therapy with oncolytic adenoviruses. J BUON (2009) 0.80
Unilateral bronchiolitis obliterans organizing pneumonia and bronchoalveolar lavage neutrophilia in a patient with parainfluenza 3 virus infection. Respir Med (1991) 0.79
Transcriptional targeting for ovarian cancer gene therapy. Gynecol Oncol (2001) 0.79
Mechanisms of chronic rejection. Transplant Proc (1999) 0.79
Short-term child psychiatric inpatient treatment. Place of residence as one-year outcome measure. Eur Child Adolesc Psychiatry (1996) 0.78
A three-dimensional assay for measurement of viral-induced oncolysis. Cancer Gene Ther (2007) 0.78
Macrophage metalloelastase (MME) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development. Cancer Gene Ther (2011) 0.78
Extended release of adenovirus from silica implants in vitro and in vivo. Gene Ther (2008) 0.77
Thermosensitivity of the reverse transcription process as an inactivation mechanism of lentiviral vectors. Hum Gene Ther (2009) 0.77
Immunobiology and pathology of chronic rejection. Transplant Proc (1997) 0.77
Expression of estrogen receptor sub-types alpha and beta in acute and chronic cardiac allograft vasculopathy. J Heart Lung Transplant (2001) 0.77
Migraine aura without headache: prevalence and risk factors in a primary eye care population. Optometry (2000) 0.77
Steroid 21-hydroxylase gene polymorphism in Addison's disease patients. Tissue Antigens (1995) 0.76
Transcomplementation of simian immunodeficiency virus Rev with human T-cell leukemia virus type I Rex. J Virol (1993) 0.75